JPH10502341A - 微小結晶製剤用の安定剤被膜としてのブチレンオキサイド−エチレンオキサイドブロック共重合体界面活性剤 - Google Patents
微小結晶製剤用の安定剤被膜としてのブチレンオキサイド−エチレンオキサイドブロック共重合体界面活性剤Info
- Publication number
- JPH10502341A JPH10502341A JP8503205A JP50320596A JPH10502341A JP H10502341 A JPH10502341 A JP H10502341A JP 8503205 A JP8503205 A JP 8503205A JP 50320596 A JP50320596 A JP 50320596A JP H10502341 A JPH10502341 A JP H10502341A
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- surfactant
- ethylene oxide
- diagnostic
- block copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/734—Fullerenes, i.e. graphene-based structures, such as nanohorns, nanococoons, nanoscrolls or fullerene-like structures, e.g. WS2 or MoS2 chalcogenide nanotubes, planar C3N4, etc.
- Y10S977/742—Carbon nanotubes, CNTs
- Y10S977/745—Carbon nanotubes, CNTs having a modified surface
- Y10S977/746—Modified with biological, organic, or hydrocarbon material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/795—Composed of biological material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/842—Manufacture, treatment, or detection of nanostructure for carbon nanotubes or fullerenes
- Y10S977/847—Surface modifications, e.g. functionalization, coating
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/89—Deposition of materials, e.g. coating, cvd, or ald
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/84—Manufacture, treatment, or detection of nanostructure
- Y10S977/895—Manufacture, treatment, or detection of nanostructure having step or means utilizing chemical property
- Y10S977/896—Chemical synthesis, e.g. chemical bonding or breaking
- Y10S977/897—Polymerization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/927—Diagnostic contrast agent
- Y10S977/928—X-ray agent
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. その表面に吸収された表面改質剤としての非イオン性の高分子界面活性剤 を有する治療又は診断薬を含む微粒子からなり、該界面活性剤はエチレンオキサ イドとブチレンオキサイドのブロック共重合体である合成物。 2. 該高分子は3,000〜5,000の分子量を有す請求項1記載の合成物 。 3. 該界面活性剤は構造 を有するトリブロック共重合体であり、 ここでRは水素又は活性水素基、x及びyは15〜700;zは5〜200であ る、 請求項1記載の合成物。 4. 該高分子は少なくとも50重量%のエチレンオキサイドからなる請求項1 記載の合成物。 5. 該診断薬はエチル3、5−ジアセトアミド−2,4,6−トリヨードベン ゾエートである請求項1記載の合成物。 6. 該診断薬は6−エトキシ−6−オキソヘキシル−3,5−ビス(アセトア ミド)−2,4,6−トリヨードベンゾエートである請求項1記載の合成物。 7. 該治療薬はダナゾールである請求項1記載の合成物。 8. その表面に吸収されたエチレンオキサイドとブチレンオキサイドの非イオ ン性ブロック共重合体を有する診断又は治療薬を含む微粒子を、該診断又は治療 薬をエチレンオキサイド及びブチレンオキサイドのブロック共重合体と安定化微 粒子を形成するのに十分な時間と条件下で接触させて製造する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/267,082 US5587143A (en) | 1994-06-28 | 1994-06-28 | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US08/267,082 | 1994-06-28 | ||
PCT/US1995/007406 WO1996000567A1 (en) | 1994-06-28 | 1995-06-09 | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanocrystal formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10502341A true JPH10502341A (ja) | 1998-03-03 |
JP3710811B2 JP3710811B2 (ja) | 2005-10-26 |
Family
ID=23017239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50320596A Expired - Fee Related JP3710811B2 (ja) | 1994-06-28 | 1995-06-09 | 微小結晶製剤用の安定剤被膜としてのブチレンオキサイド−エチレンオキサイドブロック共重合体界面活性剤 |
Country Status (15)
Country | Link |
---|---|
US (1) | US5587143A (ja) |
EP (1) | EP0804162B1 (ja) |
JP (1) | JP3710811B2 (ja) |
AT (1) | ATE205080T1 (ja) |
AU (1) | AU696655B2 (ja) |
DE (1) | DE69522584T2 (ja) |
DK (1) | DK0804162T3 (ja) |
ES (1) | ES2162925T3 (ja) |
FI (1) | FI965234A0 (ja) |
IL (1) | IL114354A (ja) |
MY (1) | MY112290A (ja) |
NO (1) | NO965455D0 (ja) |
PT (1) | PT804162E (ja) |
TW (1) | TW411276B (ja) |
WO (1) | WO1996000567A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014520779A (ja) * | 2011-07-04 | 2014-08-25 | シンジェンタ リミテッド | ミセルで被覆された結晶粒子 |
Families Citing this family (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0810853B1 (en) | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols containing nanoparticle dispersions |
IT1277376B1 (it) * | 1995-07-28 | 1997-11-10 | Euron Spa | Copolimeri a blocchi loro preparazione e loro uso come lubrificanti |
US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US20050267302A1 (en) * | 1995-12-11 | 2005-12-01 | G.D. Searle & Co. | Eplerenone crystalline form exhibiting enhanced dissolution rate |
US5993856A (en) * | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
US20050004049A1 (en) * | 1997-03-11 | 2005-01-06 | Elan Pharma International Limited | Novel griseofulvin compositions |
KR100493110B1 (ko) * | 1997-09-09 | 2005-09-12 | 주식회사 코오롱 | 열가소성합성섬유부직포및그의제조방법 |
US6884842B2 (en) | 1997-10-14 | 2005-04-26 | Alnis Biosciences, Inc. | Molecular compounds having complementary surfaces to targets |
UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US20070160675A1 (en) * | 1998-11-02 | 2007-07-12 | Elan Corporation, Plc | Nanoparticulate and controlled release compositions comprising a cephalosporin |
MXPA01004381A (es) | 1998-11-02 | 2005-09-08 | Elan Corp Plc | Composicion de multiparticulado de liberacion modificada. |
US6375986B1 (en) | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US6969529B2 (en) | 2000-09-21 | 2005-11-29 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6610317B2 (en) | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
US6656504B1 (en) | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
NZ513960A (en) | 1999-12-08 | 2004-02-27 | Pharmacia Corp | Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
UA74539C2 (en) | 1999-12-08 | 2006-01-16 | Pharmacia Corp | Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants) |
AU2041101A (en) * | 1999-12-08 | 2001-06-18 | Pharmacia Corporation | Eplerenone crystalline form |
US20030083493A1 (en) * | 1999-12-08 | 2003-05-01 | Barton Kathleen P. | Eplerenone drug substance having high phase purity |
MY120279A (en) | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
US6589557B2 (en) | 2000-06-15 | 2003-07-08 | Acusphere, Inc. | Porous celecoxib matrices and methods of manufacture thereof |
US6800297B2 (en) * | 2000-06-15 | 2004-10-05 | Acusphere, Inc. | Porous COX-2 inhibitor matrices and methods of manufacture thereof |
JP2004503601A (ja) * | 2000-07-13 | 2004-02-05 | ファルマシア・コーポレーション | 眼のcox−2媒介疾患の処置及び予防におけるcox−2阻害剤の使用法 |
US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
US7198795B2 (en) | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US6869617B2 (en) * | 2000-12-22 | 2005-03-22 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
US6951656B2 (en) * | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US6977085B2 (en) * | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US8067032B2 (en) * | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US7193084B2 (en) | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
US6976647B2 (en) * | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
CA2451161A1 (en) * | 2001-06-22 | 2003-01-03 | Elan Pharma International, Ltd. | Method for high through put screening using a small scale mill or microfluidics |
US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
CA2460867C (en) * | 2001-09-19 | 2011-04-12 | Elan Pharma International Ltd. | Nanoparticulate insulin formulations |
WO2003026662A1 (en) * | 2001-09-25 | 2003-04-03 | Pharmacia Corporation | Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
EP1429749A2 (en) | 2001-09-26 | 2004-06-23 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
US6908626B2 (en) | 2001-10-12 | 2005-06-21 | Elan Pharma International Ltd. | Compositions having a combination of immediate release and controlled release characteristics |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
WO2003039601A1 (en) * | 2001-11-07 | 2003-05-15 | Imcor Pharmaceutical Company | Methods for vascular imaging using nanoparticulate contrast agents |
US8226972B2 (en) | 2001-12-20 | 2012-07-24 | Femmepharma Holding Company, Inc. | Vaginal delivery of drugs |
CA2475092C (en) | 2002-02-04 | 2012-05-01 | Christian F. Wertz | Nanoparticulate compositions having lysozyme as a surface stabilizer |
WO2003082213A2 (en) * | 2002-03-28 | 2003-10-09 | Imcor Pharmaceutical Company | Compositions and methods for delivering pharmaceutically active agents using nanoparticulates |
US9101540B2 (en) * | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
PT1494649E (pt) | 2002-04-12 | 2012-04-11 | Alkermes Pharma Ireland Ltd | Formulações de megestrol em nanopartículas |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
US20100226989A1 (en) * | 2002-04-12 | 2010-09-09 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
ATE419835T1 (de) * | 2002-05-06 | 2009-01-15 | Elan Pharma Int Ltd | Nystatin-nanopartikelzusammensetzungen |
US7763278B2 (en) * | 2002-06-10 | 2010-07-27 | Elan Pharma International Ltd. | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
JP4776229B2 (ja) * | 2002-07-16 | 2011-09-21 | エラン ファーマ インターナショナル,リミティド | 安定なナノ粒子活性物質の液体投与組成物 |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
US7713551B2 (en) * | 2002-09-11 | 2010-05-11 | Elan Pharma International Ltd. | Gel stabilized nanoparticulate active agent compositions |
US20040173696A1 (en) * | 2002-12-17 | 2004-09-09 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
US9173836B2 (en) | 2003-01-02 | 2015-11-03 | FemmeParma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
WO2004060322A2 (en) | 2003-01-02 | 2004-07-22 | Femmepharma Holding Company, Inc. | Pharmaceutical preparations for treatments of diseases and disorders of the breast |
EP1587499A1 (en) * | 2003-01-31 | 2005-10-26 | Elan Pharma International Limited | Nanoparticulate topiramate formulations |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
DE10306761B9 (de) * | 2003-02-17 | 2004-12-23 | Völkl, Klaus Peter, Dr. | Verfahren zur Herstellung von sterilen pharmazeutischen Wirkstoffen |
US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
CA2523035C (en) * | 2003-05-22 | 2011-04-26 | Elan Pharma International Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
EP1648948B1 (en) * | 2003-07-18 | 2012-02-08 | Agency for Science, Technology and Research | Thermosensitive polymers for therapeutic use and methods of preparation |
DE602004018150D1 (de) * | 2003-08-08 | 2009-01-15 | Elan Pharma Int Ltd | Neue metaxalon-zusammensetzungen |
ES2366646T3 (es) * | 2003-11-05 | 2011-10-24 | Elan Pharma International Limited | Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial. |
US20080249076A1 (en) * | 2003-12-03 | 2008-10-09 | Lifecycle Pharma A/S | Pharmaceutical Compositions Comprising Danazol |
US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
EP2623095A1 (en) * | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
US20090155331A1 (en) * | 2005-11-16 | 2009-06-18 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
WO2006066063A1 (en) * | 2004-12-15 | 2006-06-22 | Elan Pharma International Ltd. | Nanoparticulate tacrolimus formulations |
WO2006069098A1 (en) * | 2004-12-22 | 2006-06-29 | Elan Pharma International Ltd. | Nanoparticulate bicalutamide formulations |
BRPI0606434A2 (pt) * | 2005-01-06 | 2009-06-30 | Elan Pharma Int Ltd | formulações de candesartana nanoparticulada |
AU2006214443C1 (en) | 2005-02-15 | 2011-11-24 | Alkermes Pharma Ireland Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
MX2007011502A (es) * | 2005-03-16 | 2007-12-07 | Elan Pharma Int Ltd | Formulaciones de antagonista del receptor de leucotrieno en nanoparticulas con corticosteroide. |
NZ561666A (en) | 2005-03-17 | 2010-05-28 | Elan Pharma Int Ltd | Nanoparticulate biphosphonate compositions |
KR20070121786A (ko) * | 2005-03-23 | 2007-12-27 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 코르티코스테로이드 및 항히스타민 제제 |
WO2006110802A1 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
BRPI0607537A2 (pt) * | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | formulações de derivado de quinazolina nanoparticulado |
US20060246141A1 (en) * | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
EP1954253A4 (en) | 2005-06-08 | 2011-07-27 | Elan Pharma Int Ltd | NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS |
AU2006269961B2 (en) * | 2005-07-15 | 2012-07-19 | Map Pharmaceuticals, Inc. | Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
RU2009102262A (ru) * | 2006-06-26 | 2010-08-10 | Мьючуал Фармасьютикал Компани, Инк. (Us) | Композиции активного агента, способы их получения и способы применения |
WO2008024703A1 (en) * | 2006-08-23 | 2008-02-28 | Dow Global Technologies Inc. | Aqueous compositions |
CL2007002689A1 (es) | 2006-09-18 | 2008-04-18 | Vitae Pharmaceuticals Inc | Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras. |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
BRPI0811681A2 (pt) * | 2007-06-21 | 2014-09-30 | Dow Global Technologies Inc | "composição para cuidados pessoais e método para estabilizar um componente hidrofóbico" |
US8642062B2 (en) | 2007-10-31 | 2014-02-04 | Abbott Cardiovascular Systems Inc. | Implantable device having a slow dissolving polymer |
US20090238867A1 (en) * | 2007-12-13 | 2009-09-24 | Scott Jenkins | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
US20100159010A1 (en) * | 2008-12-24 | 2010-06-24 | Mutual Pharmaceutical Company, Inc. | Active Agent Formulations, Methods of Making, and Methods of Use |
DK3045043T3 (da) | 2009-02-26 | 2020-08-03 | Relmada Therapeutics Inc | Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse |
US7828996B1 (en) | 2009-03-27 | 2010-11-09 | Abbott Cardiovascular Systems Inc. | Method for the manufacture of stable, nano-sized particles |
US20100291221A1 (en) * | 2009-05-15 | 2010-11-18 | Robert Owen Cook | Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation |
FR2945950A1 (fr) | 2009-05-27 | 2010-12-03 | Elan Pharma Int Ltd | Compositions de nanoparticules anticancereuses et procedes pour les preparer |
CA2763456C (en) | 2009-05-27 | 2017-10-24 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
US8309489B2 (en) * | 2009-06-18 | 2012-11-13 | University Of Central Florida Research Foundation, Inc. | Thermally stable nanoparticles on supports |
AR077692A1 (es) | 2009-08-06 | 2011-09-14 | Vitae Pharmaceuticals Inc | Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo |
US9012511B2 (en) | 2010-05-19 | 2015-04-21 | Alkermes Pharma Ireland Limited | Nanoparticulate cinacalcet compositions |
JP6096670B2 (ja) * | 2010-12-10 | 2017-03-15 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 酸化ケイ素誘電体膜およびポリシリコン膜を含有する基板を化学的機械的に研磨するための水性研磨組成物および方法 |
GB201111439D0 (en) * | 2011-07-04 | 2011-08-17 | Syngenta Ltd | Formulation |
EP2734204A4 (en) | 2011-07-22 | 2015-03-18 | Chemocentryx Inc | POLYMORPHIC FORMS OF 4-TERT-BUTYL-N- [4-CHLORO-2- (1-OXY-PYRIDINE-4-CARBONYL) -PHENYL] -BENZENE-SULFONAMIDE SODIUM SALT |
JP6122003B2 (ja) | 2011-07-22 | 2017-04-26 | ケモセントリックス, インコーポレイテッド | 4−tert−ブチル−N−[4−クロロ−2−(1−オキシ−ピリジン−4−カルボニル)−フェニル]−ベンゼンスルホンアミドのナトリウム塩の結晶形 |
EA027972B1 (ru) | 2011-09-01 | 2017-09-29 | Глэксо Груп Лимитед | Новая кристаллическая форма |
PT3160958T (pt) | 2014-06-25 | 2021-04-07 | Glaxosmithkline Ip Dev Ltd | Sais cristalinos de (s)-6-((1-acetilpiperidin-4-il)amino)- n-(3-(3,4-di-hidroisoquinolin-2(1h)-il)-2- hidroxipropil)pirimidina-4-carboxamida |
JP2017527574A (ja) | 2014-09-08 | 2017-09-21 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 2−(4−(4−エトキシ−6−オキソ−1,6−ジヒドロピリジン−3−イル)−2−フルオロフェニル)−n−(5−(1,1,1−トリフルオロ−2−メチルプロパン−2−イル)イソオキサゾール−3−イル)アセトアミドの結晶形 |
CN107709344B (zh) | 2015-05-01 | 2022-07-15 | 共晶制药股份有限公司 | 用于治疗黄病毒科病毒和癌症的核苷类似物 |
CA3159382A1 (en) | 2019-11-01 | 2021-05-06 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
KR20220126287A (ko) | 2019-11-14 | 2022-09-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 멀티모달 조성물 및 치료 방법 |
CN116940351A (zh) | 2021-01-15 | 2023-10-24 | 阿奎斯蒂弗医疗股份有限公司 | 前药组合物和治疗方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4535545A (en) * | 1983-11-21 | 1985-08-20 | General Dynamics, Pomona Division | Inspection device and method for cylindrical work pieces |
CA1252016A (en) * | 1984-01-09 | 1989-04-04 | Kay E. Cawiezel | Mineral dewatering method |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
IT1247529B (it) * | 1991-04-24 | 1994-12-17 | Poli Ind Chimica Spa | Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale |
US5393519A (en) * | 1992-03-27 | 1995-02-28 | Helene Curtis, Inc. | Shampoo compositions |
-
1994
- 1994-06-28 US US08/267,082 patent/US5587143A/en not_active Expired - Lifetime
-
1995
- 1995-06-09 JP JP50320596A patent/JP3710811B2/ja not_active Expired - Fee Related
- 1995-06-09 EP EP95923808A patent/EP0804162B1/en not_active Expired - Lifetime
- 1995-06-09 PT PT95923808T patent/PT804162E/pt unknown
- 1995-06-09 DE DE69522584T patent/DE69522584T2/de not_active Expired - Lifetime
- 1995-06-09 WO PCT/US1995/007406 patent/WO1996000567A1/en active IP Right Grant
- 1995-06-09 AT AT95923808T patent/ATE205080T1/de not_active IP Right Cessation
- 1995-06-09 ES ES95923808T patent/ES2162925T3/es not_active Expired - Lifetime
- 1995-06-09 DK DK95923808T patent/DK0804162T3/da active
- 1995-06-09 AU AU28240/95A patent/AU696655B2/en not_active Ceased
- 1995-06-27 IL IL11435495A patent/IL114354A/xx not_active IP Right Cessation
- 1995-06-28 MY MYPI95001774A patent/MY112290A/en unknown
- 1995-07-21 TW TW084107551A patent/TW411276B/zh not_active IP Right Cessation
-
1996
- 1996-12-18 NO NO965455A patent/NO965455D0/no not_active Application Discontinuation
- 1996-12-27 FI FI965234A patent/FI965234A0/fi unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014520779A (ja) * | 2011-07-04 | 2014-08-25 | シンジェンタ リミテッド | ミセルで被覆された結晶粒子 |
Also Published As
Publication number | Publication date |
---|---|
JP3710811B2 (ja) | 2005-10-26 |
EP0804162B1 (en) | 2001-09-05 |
NO965455L (no) | 1996-12-18 |
IL114354A (en) | 1999-06-20 |
ATE205080T1 (de) | 2001-09-15 |
DE69522584D1 (de) | 2001-10-11 |
DK0804162T3 (da) | 2002-01-07 |
WO1996000567A1 (en) | 1996-01-11 |
FI965234A (fi) | 1996-12-27 |
TW411276B (en) | 2000-11-11 |
ES2162925T3 (es) | 2002-01-16 |
DE69522584T2 (de) | 2002-07-11 |
AU2824095A (en) | 1996-01-25 |
AU696655B2 (en) | 1998-09-17 |
FI965234A0 (fi) | 1996-12-27 |
US5587143A (en) | 1996-12-24 |
MY112290A (en) | 2001-05-31 |
EP0804162A1 (en) | 1997-11-05 |
PT804162E (pt) | 2002-02-28 |
NO965455D0 (no) | 1996-12-18 |
IL114354A0 (en) | 1995-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3710811B2 (ja) | 微小結晶製剤用の安定剤被膜としてのブチレンオキサイド−エチレンオキサイドブロック共重合体界面活性剤 | |
US5569448A (en) | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions | |
US5565188A (en) | Polyalkylene block copolymers as surface modifiers for nanoparticles | |
US5326552A (en) | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants | |
AU642066B2 (en) | X-ray contrast compositions useful in medical imaging | |
RU2124886C1 (ru) | Частицы, включающие плохо растворимое кристаллическое терапевтическое или диагностическое средство, и способ их получения | |
AU662453B2 (en) | Use of charged phospholipids to reduce nanoparticle aggregation | |
JPH10502082A (ja) | 血液プール及びリンパ系のx線写真造影剤としてのジアトリゾキシエステル | |
JPH10513201A (ja) | 微結晶のための糖ベース界面活性剤 | |
JP2001518059A (ja) | 静脈内に投与されるナノ粒子−配合物−誘導有害生理学的反応の減少 | |
CA2193503C (en) | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanocrystal formulation | |
WO1996028414A1 (en) | Nanoparticulate diagnostic triiodo benzoate derivatives as x-ray contrast agents for blood pool and lymphatic system imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041207 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050307 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050606 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050726 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050811 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090819 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100819 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110819 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |